Treatment of bone disorders

Details Treatment of bone disorders Treatment of bone disorders

1993-07-27

1995-04-11

Lee, Lester L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 530303, 530307, 530324, A61K 3702, C07K 708

Patent

active

054058317

ABSTRACT:
Use of amylin, or variants of amylin, as well as amylin agonists, for the treatment of bone disorders, in particular osteoporosis, Paget's disease, and malignant deposits in bone, bone loss of malignancy or endocrine disorders or autoimmune arthritides or immobility and disuse, and in other conditions where a hypocalcaemic effect is of benefit. Functional peptide fragments of amylin, or a variant of amylin or amylin fragment, are provided as well as a soluble amylin, amylin fragments, or variants thereof, or a lyophilized product, or an oral formulation for use alone, or in combination with other agents, including insulin (or insulin-stimulating agents, including but not limited to the sulfonylureas) and estrogens, for the treatment of disorders of bone or calcium balance.

REFERENCES:
Cooper et al. PNAS USA vol. 85, 7763 (Oct. 1988).
Taggart, H. M. et al. Lancet, vol. 1, 475 (1982).
Thalassinos et al., Clin. Sci.., 62, 221-226 (1982).
Horsman et al., "The effect of estrogen dose on postmenopausal bone loss," N. Engl. J. Med., 309, 1405-1407 (1983).
Szanto J. and Sandor J., Clinical Trials J., 20, 266 (1983).
Aloia et al., "Risk factors for postmenopausal osteoporosis," Am. J. Med., 78, 95-100 (1985).
Tiegs, R. S. et al. New England Journal of Medicine, 312, 1097 (1985).
MacIntyre I. , British Medical Bulletin, 42, 343 (1986).
McEwan, J., et al. Circulation 74,1243-1247 (1986).
Cooper et al., Proceedings of the National Academy of Sciences, U.S.A., 84, 8628 (1987).
Oxford Textbook of Medicine, Eds. Weatherall, Ledingham & Warrell, p. 17.22. (Oxford Medical Publications, 2nd edition, 1987).
Oxford Textbook of Medicine, p. 10.68, supra.
Tippins, J. R., et al., Neuropeptides 4,425-434 (1987).
Breimer, L. H., Zaidi, M., MacIntyre, I, Biochem. J. 255, 377-390 (1988).
Cooper, G. J. S., et al., Proc. Natl. Acad. Sci. 85,7763-7766 (1988).
Leighton, B., Cooper, G. J. S., Nature 335,632-635 (1988).
Zaidi, M., et al. Quart. J. Exp. Physiol. 73,471-485 (1988).
Cooper et al., Biochem. Biophys. Acta, 1014, 247 (1989).
Data H. K., et al. Biochem. Biophys. Res. Commun., 162, 876 (1989).
MacIntyre, I., Lancet, 1989, Oct. 28, 1026.
Martindale, The Extra Pharmacopoeia, Ed. James E. F. Reynold, p. 1386 (London, The Pharmaceutical Press, 1989).
Martindale, p. 1339, supra.
Molecular & Cellular Biology of Diabetes Mellitus vol. III. Alan R. Liss, New York, 1989, p. 123).
Molecular and Cellular Biology of Diabetes Mellitus vol. III, ibid. p. 118.
Prager et. al. Diabetes, 1990, vol. 39, p. 116A.
Zaidi et. al., J. Endocrinol 126, 473-481 (1990).
Auch, D. et al., "Exon trap cloning: using PCR to rapidly detect and clone exons from genomic DNA fragments", Nucleic Acids Res. 18(22): 6743-7644 (1990).
Khne T., et al., "Evidence against a scanning model of RNA splicing", The EMBO Jour. 2(5): 727-733, (1983).
Wieringa, B., et al., "A Minimal Intron Length but No Specific Internal Sequence is Required for Splicing the Large Rabbit beta-Globin Intron" Cell, 37:915-925, (1984).
Buckler, A. J., et al., "Exon amplification: A strategy to isolate mammalian genes based on RNA splicing", Proc. Natl. Acad. Sci. USA, 88:4005-4009, (1991).
Malim, M. H., et al., "Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes", Nature, 335:281-283, (1988).
Taylor, et al., "The isolation of a cDNA from the Huntington's Disease Candidate region by Exon amplification", Am. J. Hum. Genet. 49(4 Suppl.). (1991).

Affiliated with

Also associated with

Rating

Treatment of bone disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of bone disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of bone disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1538551